 |
Receptor Activator of Nuclear Factor-kappa B
Research News and Information
Definition of 'Receptor Activator of Nuclear Factor-kappa B'A tumor necrosis factor receptor family member that is specific for RANK LIGAND and plays a role in bone homeostasis by regulating osteoclastogenesis. It also expressed on DENDRITIC CELLS where is plays a role in regulating dendritic cell survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS. Common names: Receptor Activator of Nuclear Factor-kappa B; Receptor Activator of Nuclear Factor kappa B; TRANCE Receptor; TRANCE-R; TRANCE R; Tumor Necrosis Factor Receptor Superfamily, Member 11a; NF-KappaB Receptor Activator; Activator, NF-KappaB Receptor; NF KappaB Receptor Activator |
Monday, November 23, 2009
Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
29 Nov 2009 
The receptor activator of nuclear factor-kappaB ligand (RANKL) plays a critical role in the differentiation and bone resorptive activity of osteoclasts. Recently, the development of anti-resorptive agents from natural substances has become a subject ... Read more...
Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin.
6 Oct 2009 Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-kappaB (RANK), were identified in a man with celiac disease who presented with severe ... Read more...
[Hepato-biliary and pancreatic disease and osteodystrophy]
30 Aug 2009 It is well known that insulin resistance affects osteodystrophy, and there is an important relationship between insulin resistance and hepato-biliary disease. It is also well known that hepato-biliary and pancreatic disease is associated with ... Read more...
Latest indexed articles for 'Receptor Activator of Nuclear Factor-kappa B'
These are the very latest articles for this heading:
- Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. 29 Nov 2009
- Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. 6 Oct 2009
- [Hepato-biliary and pancreatic disease and osteodystrophy] 30 Aug 2009
- Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy. 30 Aug 2009
- Pathways in external apical root resorption associated with orthodontia. 30 Jul 2009
- Osteopetrosis--more than only a disease of the bone.
30 Jul 2009 - A single-center experience in 20 patients with infantile malignant osteopetrosis. 30 Jul 2009
- Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. 30 Jul 2009
- Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. 30 Jul 2009
- Regulation of dendritic cell survival and cytokine production by osteoprotegerin. 27 Jul 2009
- IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. 20 Jul 2009
- The mechanism of osteoclast differentiation induced by IL-1. 6 Jul 2009
- Early onset Paget's disease of bone caused by a novel mutation (78dup27) of the TNFRSF11A gene in a Chinese family. 4 Jul 2009
- Receptor activator of nuclear factor kappa B ligand-mediated osteoclastogenesis is elevated in ankylosing spondylitis. 29 Jun 2009
- Non-association between polymorphisms of the frizzled receptor genes and bone mineral density in postmenopausal Korean women.
10 Jun 2009 - A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level. 30 May 2009
- Alumina ceramic particles, in comparison with titanium particles, hardly affect the expression of RANK-, TNF-alpha-, and OPG-mRNA in the THP-1 human monocytic cell line. 30 May 2009
- Crystallization and preliminary X-ray analysis of mouse RANK and its complex with RANKL. 20 May 2009
- Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians. 19 May 2009
- [The participation of RANK, RANKL and OPG in tumor osteolysis] 13 May 2009
See a longer list of these articles.
Technical information about 'Receptor Activator of Nuclear Factor-kappa B'
Definition: A tumor necrosis factor receptor family member that is specific for RANK LIGAND and plays a role in bone homeostasis by regulating osteoclastogenesis. It also expressed on DENDRITIC CELLS where is plays a role in regulating dendritic cell survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Registry Number: 0
Descriptor UI: D053246
Alternative terms: Receptor Activator of Nuclear Factor-kappa B; Receptor Activator of Nuclear Factor kappa B; TRANCE Receptor; TRANCE-R; TRANCE R; Tumor Necrosis Factor Receptor Superfamily, Member 11a; NF-KappaB Receptor Activator; Activator, NF-KappaB Receptor; NF KappaB Receptor Activator; Receptor Activator, NF-KappaB; Receptors, Tumor Necrosis Factor, Member 11a; TNFRSF11A Protein; RANK Protein; Receptor Activator of NF-kappa B; Receptor Activator of NF kappa B; Receptor Activator of NF-kappaB; Receptor Activator of NF kappaB; Receptor Activator of Nuclear Factor-kappaB; Receptor Activator of Nuclear Factor kappaB; NF-Kappa B Receptor Activator; NF Kappa B Receptor Activator;
Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;
Tree Number: D12.776.543.750.705.852.760.345;
History Note: 2007(1997)